ZURICH (Reuters) – Roche extended its offer on Monday

hostile 5.7 billion dollars in cash to buy the

American signing of genetic Illumina, demonstrating the

will of the Swiss pharmaceutical expected, a strategy of

acquisitions that you given good results earlier.

But analysts believe it Roche, has had success with its

hostile offers, eventually will have to improve its proposal of

44,50 dollars per share to convince Illumina, whose

shares closed on Friday at $51,22.

Illumina has already adopted a defensive strategy of “pill

“”

poisoned” against the unsolicited offer from Roche and it has

advised its shareholders that do not offer any of its

actions, arguing that the price is too low.

“Extension of Roche was expected,” said Illumina. “A

Figure extremely low actions has come (the offer),

consistent with our vision – and our shareholder – of

that the offer Roche did not reflect the unique leadership position

of Illumina, performance of business and future prospects”.

Roche have been offered so far, only 0.1%

the company said the shares of Illumina in circulation,

Switzerland, it is headquartered in Basel.

Roche shares fell 0.63 percent to 158.3

Swiss francs, with performance better than the recoil of a

1.3% of its industry.

“In the long run, consider that Roche will convince Illumina.

“”

Could take about six to twelve months and a best offer”, said

analysts of the Bank Vontobel.

“In general, we like the acquisition and we believe that

“

will serve to create value once it is integrated in the network of

“

Roche”, added.

Previous acquisitions such as the signature of testing of

Diagnostics window and the American Group of

biotech Genentech show that Roche likes taking

time in their acquisitions and which will ultimately prevail by

means of a best offer.

Illumina, which is headquartered in San Diego, develops

machines that decidifican the whole of a person going genome

beyond simple genetic tests already used for

diseases such as cancer to do some tests

genetic variations.

An agreement giving Roche Diagnostics unit a

leading position in the market of genetic sequencing, which

can help better identify patients benefit from

a specific drug.